Aurora Other Liab from 2010 to 2024

ACB Stock  USD 4.55  0.01  0.22%   
Aurora Cannabis' Other Liabilities is increasing over the years with slightly volatile fluctuation. Overall, Other Liabilities is expected to go to about 67.7 M this year. From 2010 to 2024 Aurora Cannabis Other Liabilities quarterly data regression line had arithmetic mean of  43,130,501 and r-squared of  0.14. View All Fundamentals
 
Other Liabilities  
First Reported
2014-09-30
Previous Quarter
86.9 M
Current Value
75.3 M
Quarterly Volatility
85.5 M
 
Yuan Drop
 
Covid
Check Aurora Cannabis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aurora Cannabis' main balance sheet or income statement drivers, such as Interest Expense of 19.2 M, Other Operating Expenses of 195.6 M or EBITDA of 21.5 M, as well as many indicators such as Price To Sales Ratio of 0.97, Dividend Yield of 0.0 or PTB Ratio of 0.47. Aurora financial statements analysis is a perfect complement when working with Aurora Cannabis Valuation or Volatility modules.
  
Check out the analysis of Aurora Cannabis Correlation against competitors.
For information on how to trade Aurora Stock refer to our How to Trade Aurora Stock guide.

Latest Aurora Cannabis' Other Liab Growth Pattern

Below is the plot of the Other Liab of Aurora Cannabis over the last few years. It is Aurora Cannabis' Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aurora Cannabis' overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Slightly volatile
   Other Liab   
       Timeline  

Aurora Other Liab Regression Statistics

Arithmetic Mean43,130,501
Geometric Mean0.00
Coefficient Of Variation167.16
Mean Deviation43,794,268
Median16,464,000
Standard Deviation72,096,577
Sample Variance5197.9T
Range280.3M
R-Value0.37
Mean Square Error4834.9T
R-Squared0.14
Significance0.18
Slope5,951,166
Total Sum of Squares72770.8T

Aurora Other Liab History

202467.7 M
202346.3 M
202140.3 M
202092 M
20195.8 M
2018280.3 M
201757.7 M

About Aurora Cannabis Financial Statements

Aurora Cannabis stakeholders use historical fundamental indicators, such as Aurora Cannabis' Other Liab, to determine how well the company is positioned to perform in the future. Although Aurora Cannabis investors may analyze each financial statement separately, they are all interrelated. For example, changes in Aurora Cannabis' assets and liabilities are reflected in the revenues and expenses on Aurora Cannabis' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Aurora Cannabis. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Liabilities46.3 M67.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Aurora Cannabis offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurora Cannabis' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurora Cannabis Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurora Cannabis Stock:
Check out the analysis of Aurora Cannabis Correlation against competitors.
For information on how to trade Aurora Stock refer to our How to Trade Aurora Stock guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurora Cannabis. If investors know Aurora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurora Cannabis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.92)
Earnings Share
(0.46)
Revenue Per Share
0.033
Quarterly Revenue Growth
0.285
Return On Assets
(0.01)
The market value of Aurora Cannabis is measured differently than its book value, which is the value of Aurora that is recorded on the company's balance sheet. Investors also form their own opinion of Aurora Cannabis' value that differs from its market value or its book value, called intrinsic value, which is Aurora Cannabis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurora Cannabis' market value can be influenced by many factors that don't directly affect Aurora Cannabis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurora Cannabis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurora Cannabis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurora Cannabis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.